keyword
MENU ▼
Read by QxMD icon Read
search

Eye anti-VEGF

keyword
https://www.readbyqxmd.com/read/29305324/real-world-outcomes-in-patients-with-neovascular-age-related-macular-degeneration-treated-with-intravitreal-vascular-endothelial-growth-factor-inhibitors
#1
REVIEW
Hemal Mehta, Adnan Tufail, Vincent Daien, Aaron Lee, Vuong Nguyen, Mehmet Ozturk, Daniel Barthelmes, Mark C Gillies
Clinical trials identified intravitreal vascular endothelial growth factor inhibitors (anti-VEGF agents) have the potential to stabilise or even improve visual acuity outcomes in neovascular age-related macular degeneration (AMD), a sight-threatening disease. Real-world evidence allows us to assess whether results from randomised controlled trials can be applied to the general population. We describe the development of global registries, in particular the Fight Retinal Blindness! registry that originated in Australia, the United Kingdom AMD Electronic Medical Records User Group and the IRIS registry in the USA...
January 2, 2018: Progress in Retinal and Eye Research
https://www.readbyqxmd.com/read/29302789/hyperpigmented-spots-after-treatment-for-submacular-hemorrhage-secondary-to-polypoidal-choroidal-vasculopathy
#2
Jae Hui Kim, Young Suk Chang, Chul Gu Kim, Dong Won Lee, Jung Il Han
PURPOSE: To investigate the characteristics and clinical course of hyperpigmented spots after submacular hemorrhage secondary to polypoidal choroidal vasculopathy (PCV). METHODS: This retrospective, observational study included 87 eyes initially treated with three anti-vascular endothelial growth factor (VEGF) injections for submacular hemorrhage secondary to PCV. Patients were divided into two groups according to the presence of multiple small, dark-gray or black, pigmented lesions after initial treatment: the hyperpigmented spots group and no-hyperpigmented spots group...
January 4, 2018: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/29290015/changes-in-systemic-vascular-endothelial-growth-factor-levels-after-intravitreal-injection-of-aflibercept-in-infants-with-retinopathy-of-prematurity
#3
Chung-Ying Huang, Reyin Lien, Nan-Kai Wang, An-Ning Chao, Kuan-Jen Chen, Tun-Lu Chen, Yih-Shiou Hwang, Chi-Chun Lai, Wei-Chi Wu
BACKGROUND: To investigate the levels of VEGF in the systemic circulation of patients with type 1 ROP who received intravitreal injections of 1 mg (0.025 mL) aflibercept (IVA) or 0.625 mg (0.025 mL) bevacizumab (IVB). METHODS: Patients who had type 1 ROP and received either IVA or IVB were enrolled in this prospective study. Serum and plasma samples were collected prior to and up to 12 weeks after IVB or IVA treatment. The serum and plasma VEGF levels were measured using enzyme-linked immunosorbent assays (ELISAs), and the platelet levels in the blood were also quantified...
December 30, 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/29280367/intravitreal-bevacizumab-in-diabetic-retinopathy-recommendations-from-the-pan-american-collaborative-retina-study-group-pacores-the-2016-knobloch-lecture
#4
J Fernando Arevalo, T Y Alvin Liu
The advent of intravitreal anti-vascular endothelial growth factor (anti-VEGF) medications has revolutionized the treatment of diabetic eye diseases. Herein, we report the outcomes of clinical studies carried out by the Pan-American Collaborative Retina Study Group (PACORES), with a specific focus on the efficacy of intravitreal bevacizumab in the management of diabetic macular edema and proliferative diabetic retinopathy. We will also discuss the use of intravitreal bevacizumab as a preoperative, adjuvant therapy before vitrectomy for proliferative diabetic retinopathy...
December 27, 2017: Asia-Pacific Journal of Ophthalmology
https://www.readbyqxmd.com/read/29279602/new-therapeutic-perceptions-in-a-patient-with-complicated-herpes-simplex-virus-1-keratitis-a-case-report-and-review-of-the-literature
#5
REVIEW
Dimitrios Kalogeropoulos, Aliki Geka, Konstantinos Malamos, Maria Kanari, Chris Kalogeropoulos
BACKGROUND Keratitis caused by herpes simplex virus (HSV) can have detrimental effects on the cornea leading to loss of vision. Modern therapies can contribute to the prevention of anatomical and functional damage. CASE REPORT An 80-year-old male with complicated HSV-1 keratitis of the left eye (confirmed diagnosis after microbiological investigation) presented three months after antiviral treatment with corneal blurring, severe epitheliopathy, thinning of the stroma, and neovascularization. At the time he was referred, the visual acuity of his left eye was very low, as he could only count fingers at a one-foot distance...
December 27, 2017: American Journal of Case Reports
https://www.readbyqxmd.com/read/29217515/choroidal-neovascular-membrane-in-paediatric-patients-clinical-characteristics-and-outcomes
#6
Tapas Ranjan Padhi, Bradley J Anderson, Ashkan M Abbey, Yoshihiro Yonekawa, Maxwell Stem, Danish Alam, Rohit Ramesh Modi, Laxmi Prabhavathi Savla, Michael T Trese, Antonio Capone, Kimberly A Drenser, Cagri G Besirli
PURPOSE: To analyse the clinical characteristics and treatment outcomes of choroidal neovascular membranes (CNVM) in paediatric subjects at three paediatric retina referral centres. METHODS: Medical charts of patients aged 18 years or less with a diagnosis of CNVM were retrospectively reviewed. The demographic profile, laterality, presenting complaint, corrected vision, underlying pathology, fundus, fundus fluorescein angiogram and optical coherence tomogram (OCT) were analysed...
December 7, 2017: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/29207076/antiangiogenic-effects-of-catalpol-on-rat-corneal%C3%A2-neovascularization
#7
Yun Han, Mei Shen, Li-Yuan Tang, Gang Tan, Qi-Chen Yang, Lei Ye, Lin-Hong Ye, Nan Jiang, Gui-Ping Gao, Yi Shao
To investigate the effects of catalpol on corneal neovascularization (CNV) and associated inflammation, eye drops (5 mM catalpol or PBS) were administered four times daily to alkali‑burn rat models of CNV and inflammation. Clinical evaluations of CNV and the degree of inflammation were performed on days 0, 4, 7, 10 and 14 under slit lamp microscopy. Eyes were collected on day 14 and prepared for hematoxylin and eosin, and immunofluorescence staining; corneal cell apoptosis was investigated via terminal deoxynucleotidyl transferase‑mediated nick end labeling (TUNEL) staining...
November 20, 2017: Molecular Medicine Reports
https://www.readbyqxmd.com/read/29205985/current-care-guideline-age-related-macular-degeneration-amd
#8
(no author information available yet)
Age-related macular degeneration (AMD) is the main cause of visual impairment in developed countries. Several improvements in the visualization of posterior segment of the eye together with the introduction of intravitreal anti-VEGF treatment have revolutionized the prognosis of the wet form of AMD (wAMD). Increasing incidence of wAMD together with the limited resources of the healthcare systems pose challenges for the provision and development of care. In context of these current aspects, we aim to set evidence-based guidelines for diagnosis, treatment and follow-up of patients with wAMD...
2017: Duodecim; Lääketieteellinen Aikakauskirja
https://www.readbyqxmd.com/read/29204069/the-role-of-focal-laser-in-the-anti-vascular-endothelial-growth-factor-era
#9
REVIEW
Jason N Crosson, Lauren Mason, John O Mason
Introduction: To review important studies examining focal laser for diabetic macular edema (DME), to examine real-world data regarding actual treatments patients are receiving, to present long-term visual outcomes in real-world practice, and to suggest an evidence-based approach for the use of focal laser. Methods: This study is a review of landmark studies evaluating focal laser and pharmacologic therapy for DME. In addition, the authors include a retrospective review of 102 consecutive eyes of 53 patients in our practice setting in rural Alabama...
2017: Ophthalmology and Eye Diseases
https://www.readbyqxmd.com/read/29196768/macular-atrophy-development-and-subretinal-drusenoid-deposits-in-anti-vascular-endothelial-growth-factor-treated-age-related-macular-degeneration
#10
Anna V Zarubina, Orly Gal-Or, Carrie E Huisingh, Cynthia Owsley, K Bailey Freund
Purpose: To explore the association between presence of subretinal drusenoid deposits (SDD) at baseline in eyes with neovascular age-related macular degeneration (nAMD) with the development of macular atrophy (MA) during anti-vascular endothelial growth factor (VEGF) therapy. Methods: There were 74 eyes without pre-existing MA receiving anti-VEGF therapy for nAMD for 2 years or longer analyzed. At least two image modalities that included spectral-domain optical coherence tomography, near-infrared reflectance, fluorescein angiography, and color fundus photos were used to assess for SDD presence, phenotype (dot and ribbon), and location, neovascularization type, and MA...
December 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/29185408/high-altitude-retinopathy-presenting-as-central-retinal-vein-occlusion-in-a-soldier
#11
Waseem Raja, Ahsan Mukhtar
A 33-year soldier, deployed at an altitude of 3,350 meters for two years, developed unilateral Central Retinal Vein Occlusion (CRVO) in the left eye. He had no risk factor for thrombosis and all thrombophilia screenings were negative. The patient was managed with intravitreal injections of anti-VEGF (Bevacizumab) every four weeks. He showed gradual improvement in the visual acuity over the next 3 months. Best corrected visual acuity (BCVA) after three months was 6/7.5; whereas, initially it was limited to hand movements only...
December 2017: Journal of the College of Physicians and Surgeons—Pakistan: JCPSP
https://www.readbyqxmd.com/read/29184088/comparison-of-two-year-outcomes-after-photodynamic-therapy-with-ranibizumab-or-aflibercept-for-polypoidal-choroidal-vasculopathy
#12
Wataru Kikushima, Yoichi Sakurada, Atsushi Sugiyama, Seigo Yoneyama, Naohiko Tanabe, Mio Matsubara, Fumihiko Mabuchi, Hiroyuki Iijima
Photodynamic therapy (PDT) combined with intravitreal anti-vascular endothelial growth factor (VEGF) agents is currently the first-line treatment for polypoidal choroidal vasculopathy (PCV), along with anti-VEGF monotherapy. In this study, 100 eyes with treatment-naïve PCV were initially treated with PDT combined with intravitreal ranibizumab (IVR; n = 57) or aflibercept (IVA; n = 43). We compared two-year outcomes between these two groups and investigated factors associated with visual improvement and retreatment over 24 months...
November 28, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29180844/vitreoretinal-interface-abnormalities-in-diabetic-macular-edema-and-effectiveness-of-anti-vegf-therapy-an-optical-coherence-tomography-study
#13
Alexei N Kulikov, Sergei V Sosnovskii, Roman D Berezin, Dmitrii S Maltsev, Dzhambulat H Oskanov, Nikolai A Gribanov
Purpose: To study vitreoretinal interface (VRI) abnormalities in diabetic macular edema (DME) and the influence of these on the effectiveness of intravitreal anti-vascular endothelial growth factor (VEGF) therapy. Methods: VRI status and central retinal thickness (CRT) were evaluated using line and 3D-reference scans obtained using spectral domain-optical coherence tomography RTVue-100 before and 1 month after intravitreal anti-VEGF injection (IVI). VRI status was categorized into five subgroups: normal VRI, retinal surface wrinkling associated with the eccentric epiretinal membrane (ERM), ERM involving the macular center, vitreomacular adhesion (VMA), and vitreomacular traction (VMT)...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/29179221/-vitreomacular-traction-following-anti-vegf-therapy-two-cases
#14
Sophie Helene Wallraf, Kristina Markova, Christos Haritoglou
Vitreomacular traction syndrome (VMTS) is defined as an incomplete or anomalous posterior vitreous detachment resulting in tractional forces at the macular region. In the context of anti-VEGF therapy, the formation of vitreoretinal traction has mainly been reported as a potential complication of VEGF inhibition in ischemic proliferative retinal disease, such as proliferative diabetic retinopathy. In this report, we present two patients who developed VMTS during anti-VEGF therapy for exudative age-related macular degeneration and diabetic macular edema...
November 27, 2017: Klinische Monatsblätter Für Augenheilkunde
https://www.readbyqxmd.com/read/29166140/comparison-of-short-term-choroidal-thickness-and-retinal-morphological-changes-after-intravitreal-anti-vegf-therapy-with-ranibizumab-or-aflibercept-in-treatment-naive-eyes
#15
Magda Gharbiya, Rosalia Giustolisi, Jessica Marchiori, Alice Bruscolini, Fabiana Mallone, Valeria Fameli, Marcella Nebbioso, Solmaz Abdolrahimzadeh
PURPOSE: To evaluate choroidal thickness (CT) and retinal morphological changes in eyes with neovascular age-related macular degeneration (nAMD) following ranibizumab or aflibercept intravitreal treatment. MATERIALS AND METHODS: This was a prospective, observational, comparative study where 76 eyes of 76 consecutive patients with treatment-naive nAMD were consecutively enrolled and randomized to ranibizumab 0.5 mg or aflibercept 2 mg injections. Spectral-domain optical coherence tomography images of the choroid were obtained by enhanced depth imaging modality...
November 22, 2017: Current Eye Research
https://www.readbyqxmd.com/read/29148027/sequential-tissue-plasminogen-activator-pneumatic-displacement-and-anti-vegf-treatment-for-submacular-hemorrhage
#16
Handan Bardak, Yavuz Bardak, Yeşim Erçalık, Burak Erdem, Gökhan Arslan, Semrin Timlioglu
PURPOSE: To report the results of our sequential intravitreal (IV) tissue plasminogen activator (tPA), pneumatic displacement (PD), and IV anti-vascular endothelial growth factor (VEGF) treatment in patients with neovascular age-related macular degeneration (nAMD)-related submacular hemorrhage (SMH). METHODS: A total of 16 eyes of 16 patients with SMH of less than 15 days duration were included in this retrospective pilot study. The tPA was applied on the day of diagnosis, and PD was performed the following day...
November 4, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/29137019/optical-coherence-tomography-angiography-in-patients-with-diabetic-retinopathy-treated-with-anti-vegf-intravitreal-injections-case-report
#17
Katarzyna Michalska-Małecka, Anna Heinke Knudsen
PURPOSE: To present optical coherence tomography angiography (OCTA) features in patients with diabetic retinopathy (DR) at the baseline and in response to treatment with anti-VEGF intravitreal injections. To investigate the role of OCTA in management of patients with DR. METHODS: Retrospective case series showing primary outcomes of 3 patients with DR and diabetic macular edema. Patients were injected intravitreally a loading phase of 3 monthly 2.0 mg aflibercept, followed by 2 injections bimonthly (5 injections in total)...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29134820/pharmacokinetics-of-intravitreal-anti-vegf-drugs-in-vitrectomized-versus-non-vitrectomized-eyes
#18
Magdalena Edington, Julie Connolly, Ngaihang Victor Chong
Introduction The review aims to discuss effects of vitrectomy on pharmacokinetics of anti-vascular endothelial growth factor (anti-VEGF) agents, and attempt to provide treatment guidance. Areas Covered An Embase search was conducted using the terms 'anti-VEGF', 'pegaptanib', 'ranibizumab', 'bevacizumab', 'aflibercept', 'pharmacokinetics', 'half-life', 'clearance', 'metabolism', 'vitrectomy', 'vitrectomized'. Published data regarding the pharmacokinetic properties of the above drugs and the effect of vitrectomy in animal and human eyes was reviewed...
November 14, 2017: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/29131696/risk-factors-for-discontinuation-of-treatment-for-neovascular-age-related-macular-degeneration
#19
Inger Westborg, Aldana Rosso
PURPOSE: To investigate risk factors for treatment discontinuation for neovascular age-related macular degeneration (nAMD). METHODS: Data from the Swedish Macula Register and the Skåne Healthcare Register are reported on the treatment received by 932 nAMD patients diagnosed 2013-2015. Treatment discontinuation is defined as having a termination visit or lacking a control or treatment visit during the period of 10-14 months after the diagnostic visit. The risk of treatment discontinuation during the first year is estimated using a Poisson model and a classification tree...
November 13, 2017: Ophthalmic Epidemiology
https://www.readbyqxmd.com/read/29127949/effect-of-adding-dexamethasone-to-continued-ranibizumab-treatment-in-patients-with-persistent-diabetic-macular-edema-a-drcr-network-phase-2-randomized-clinical-trial
#20
Raj K Maturi, Adam R Glassman, Danni Liu, Roy W Beck, Abdhish R Bhavsar, Neil M Bressler, Lee M Jampol, Michele Melia, Omar S Punjabi, Hani Salehi-Had, Jennifer K Sun
Importance: Some eyes have persistent diabetic macular edema (DME) following anti-vascular endothelial growth factor (anti-VEGF) therapy for DME. Subsequently adding intravitreous corticosteroids to the treatment regimen might result in better outcomes than continued anti-VEGF therapy alone. Objective: To compare continued intravitreous ranibizumab alone with ranibizumab plus intravitreous dexamethasone implant in eyes with persistent DME. Design, Setting, and Participants: Phase 2 multicenter randomized clinical trial conducted at 40 US sites in 129 eyes from 116 adults with diabetes between February 2014 and December 2016...
November 11, 2017: JAMA Ophthalmology
keyword
keyword
36614
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"